Array grants Aslan full rights to varlitinib

Array BioPharma Inc. (NASDAQ:ARRY) granted Aslan Pharmaceuticals Ltd. (TPEx:6497) exclusive, worldwide rights to develop and commercialize cancer candidate varlitinib (ASLAN001). The

Read the full 219 word article

User Sign In